Get Live Data

focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied Materials
Stephen Yiu, FM at WS Blue Whale, discusses Nvidia, Visa/Mastercard, Lam Research & Allied MaterialsView Video
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to mining
Ben Turney, CEO at Kavango Resources, explains the company's progress from exploration to miningView Video

Latest Share Chat

  2. Share Prices
  3. Syncona Share Price
  4. Syncona Share News
  5. IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Pin to quick picksSyncona Share News (SYNC)

Syncona Information

Share Price Information for Syncona (SYNC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 112.20
Bid: 112.00
Ask: 113.00
Change: -2.60 (-2.26%)
Spread: 1.00 (0.893%)
Open: 114.00
High: 114.20
Low: 112.20
Prev. Close: 114.80
SYNC Live PriceLast checked at -
Syncona is an Investment Trust

To deliver superior long-term capital appreciation from investments in life science businesses, leading long-only and alternative investment funds and managed accounts across multiple asset classes.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Syncona notes FDA acceptance of Autolus's BLA for obe-cel

Mon, 22nd Jan 2024 12:19

Syncona Ltd - London-based investor in healthcare companies - The US Food & Drug Administration accepts Autolus Therapeutics PLC's biologics licence application for obe-cel for patients with relapsed/refractory adult B-cell acute lymphoblastic leukaemia. The FDA has set a target action date of November 16 for reviewing the application, Syncona says. Further, Autolus is on track to submit a marketing authorisation application to the EU's European Medicines Agency in the first half of 2024.

Syncona has an 18% stake in Autolus.

Current stock price: 117.05 pence, down 0.3% on Monday

12-month change: down 31%

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
5 Feb 2021 08:01

Syncona investment Achilles upbeat on safety review of trials

(Sharecast News) - Healthcare investor Syncona said on Friday that its portfolio company Achilles Therapeutics, which is developing precision T-cell therapies to treat solid tumours, had announced that an independent data and safety monitoring committee had completed the first review of the ongoing, first-in-human phase 1 and 2 'CHIRON' and 'THETIS' trials.

Read more
6 Jan 2021 09:30

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Syncona Investee Autolus To Focus On Adult Leukemia Programme in 2021

Read more
6 Jan 2021 08:36

Syncona upbeat on developments at Autolus

(Sharecast News) - Life science investor Syncona updated the market on its portfolio company Autolus on Wednesday, announcing that it would prioritise the development of the 'AUTO1' programme for adult acute lymphoblastic leukemia (ALL), based on the positive data generated in its phase 1 and 2 studies to date and a high unmet medical need.

Read more
21 Dec 2020 15:43

UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs

UK EXECUTIVE CHANGE SUMMARY: Ferguson Taps Former Ashtead, Bunzl Execs

Read more
19 Nov 2020 10:12

Syncona Portfolio Companies Boost Interim Result; Launches New Company

Syncona Portfolio Companies Boost Interim Result; Launches New Company

Read more
19 Nov 2020 08:16

Syncona reports improved performance for past six months as clinical trials resume

(Sharecast News) - Healthcare company Syncona reported a "robust" performance for the six months up to 30 September in which its net assets reached a value of £1,366.7m at 203,4p per share and a net asset value total return of 9.6% in the period.

Read more
12 Nov 2020 15:55

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
2 Nov 2020 16:54

UK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse

UK EXECUTIVE CHANGE SUMMARY: Kakuzi Acts To Prevent Human Rights Abuse

Read more
30 Oct 2020 10:06

Syncona Investee Freeline Posts Widened Interim Loss On Higher Costs

Syncona Investee Freeline Posts Widened Interim Loss On Higher Costs

Read more
30 Oct 2020 09:21

Syncona portfolio company sees interim losses widen

(Sharecast News) - Healthcare investment firm Syncona said on Friday that portfolio business Freeline Therapeutics had seen interim losses widen as a result of increased research and development costs.

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
10 Aug 2020 09:19

Syncona Life Science Portfolio Boosted By Autolus And Freeline

Syncona Life Science Portfolio Boosted By Autolus And Freeline

Read more
7 Aug 2020 09:44

Syncona Investee Freeline Therapeutics Prices IPO In New York

Syncona Investee Freeline Therapeutics Prices IPO In New York

Read more
7 Aug 2020 08:17

Syncona portfolio company Freeline prices US IPO

(Sharecast News) - Healthcare investment company Syncona announced on Friday that its portfolio company Freeline Therapeutics has priced its initial public offering in the United States.

Read more
3 Aug 2020 22:16

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

UK TRADING UPDATE SUMMARY: Bluebird To Buy Southern Gold Venture Stake

Read more
67891011121314

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.